# OnCo record paper-niagara-nejm-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-niagara-nejm-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-niagara-nejm-2024" ;
  schema:name "NIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer"@en ;
  schema:description "Adding the immunotherapy durvalumab to chemotherapy before bladder removal, and continuing it afterwards, reduced relapse and death in muscle-invasive bladder cancer, the first improvement on neoadjuvant chemotherapy in two decades."@en ;
  schema:url <https://onco.cc/key-papers/paper-niagara-nejm-2024/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2408154>, <https://clinicaltrials.gov/study/NCT03732677> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2408154> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Powles T, Catto JWF, Galsky MD, et al." ;
  onco:cancers <https://onco.cc/cancers/urothelial/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/platinum/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/durvalumab/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:institutions <https://onco.cc/institutions/mount-sinai/> ;
  onco:terms <https://onco.cc/terms/efs/>, <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/neoadjuvant-adjuvant/> ;
  onco:people <https://onco.cc/people/matthew-galsky/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-immunotherapy-response/>, <https://onco.cc/bottlenecks/b-trial-design/>, <https://onco.cc/bottlenecks/b-dormancy-mrd/> ;
  onco:journals <https://onco.cc/journals/nejm/> .